Related references
Note: Only part of the references are listed.Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers
Thomas M. van Himbergen et al.
JOURNAL OF LIPID RESEARCH (2009)
Alterations in cholesterol absorption/synthesis markers characterize Framingham Offspring Study participants with CHD
Nirupa R. Matthan et al.
JOURNAL OF LIPID RESEARCH (2009)
Comprehensive lipid management versus aggressive low-density lipoprotein lowering to reduce cardiovascular risk
Robert H. Knopp et al.
AMERICAN JOURNAL OF CARDIOLOGY (2008)
Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER
Eliana Polisecki et al.
ATHEROSCLEROSIS (2008)
Primary prevention of cardiovascular diseases among hypercholesterolemic Japanese with a low dose of pravastatin
H. Nakamura
ATHEROSCLEROSIS SUPPLEMENTS (2007)
A systematic review and economic evaluation of statins for the prevention of coronary events
S. Ward et al.
HEALTH TECHNOLOGY ASSESSMENT (2007)
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
C Baigent et al.
LANCET (2005)
Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype*17
M Niemi et al.
PHARMACOGENETICS AND GENOMICS (2005)
Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment
BJ Ansell et al.
CIRCULATION (2003)
Impact of simvastatin, niacin, and/or antioxidants on cholesterol metabolism in CAD patients with low HDL
NR Matthan et al.
JOURNAL OF LIPID RESEARCH (2003)
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
J Shepherd et al.
LANCET (2002)
Ineffective decrease of serum cholesterol by simvastatin in a subgroup of hypercholesterolemic coronary patients
TA Miettinen et al.
ATHEROSCLEROSIS (2002)
Baseline intestinal absorption and synthesis of cholesterol regulate its response to hypolipidaemic treatments in coronary patients
H Gylling et al.
ATHEROSCLEROSIS (2002)
Noncholesterol sterols and cholesterol lowering by long-term simvastatin treatment in coronary patients - Relation to basal serum cholestanol
TA Miettinen et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2000)
Share Paper
